Daniel D. Shoemaker is CSO at FATE THERAPEUTICS INC (FATE). They have made 10 open-market trades across 1 company since 2014, most recently 2021-03-08.
CIK 0001586892
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 10 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| FATE | 79,448 | $141K |
Shares reported on the most recent Form 4, priced at the 2021-03-09 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| FATE | SELL | 2021-03-08 | 2021-03-09 | $81.41 | $3.8M | -1.5% | -13.8% | -16.0% |
| FATE | SELL | 2021-01-08 | 2021-01-12 | $114.75 | $1.7M | -15.1% | -9.5% | -33.8% |
| FATE | SELL | 2020-11-16 | 2020-11-16 | $51.83 | $2.6M | +11.0% | +76.5% | +94.5% |
| FATE | SELL | 2020-09-14 | 2020-09-16 | $36.33 | $1.8M | +12.2% | +34.7% | +157.0% |
| FATE | SELL | 2020-01-08 | 2020-01-10 | $20.70 | $118K | +13.5% | +22.1% | +24.4% |
| FATE | SELL | 2019-12-30 | 2020-01-02 | $19.49 | $973K | +28.5% | +43.5% | +6.9% |
| FATE | SELL | 2019-10-15 | 2019-10-16 | $14.29 | $169K | +5.4% | +1.0% | +66.9% |
| FATE | SELL | 2019-06-27 | 2019-06-28 | $20.21 | $253K | -0.3% | +8.1% | -23.5% |
| FATE | SELL | 2019-03-28 | 2019-03-29 | $16.94 | $424K | -2.3% | -1.0% | +15.7% |
| FATE | SELL | 2017-10-13 | 2017-10-17 | $3.87 | $51K | +10.5% | +5.1% | +59.4% |
| FATE | SELL · 10b5-1 | 2014-03-31 | 2014-04-02 | $9.86 | $85K | -21.5% | -1.8% | -1.8% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.